Microbial microcapsules based on grape seed polyphenol-metal network and modified starch, preparation method and application in improving gut health
By using a bilayer composite microcapsule technology of grape seed polyphenol-metal network and modified starch, the problems of low survival rate of probiotics in the gastrointestinal environment and poor controllability of intestinal release have been solved, achieving efficient probiotic delivery and intestinal health improvement effects. Both in vivo and in vitro experiments have shown excellent protective and anti-inflammatory effects.
Patent Information
- Application Number
- CN202611554104.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-09
- Publication Date
- 2026-11-10
AI Technical Summary
Existing microencapsulation technology has limitations in protecting probiotics, including limited protection of single-layer encapsulation systems, poor controllability of intestinal release, insufficient density of traditional starch-based materials, and complex and incompatible processes of multi-layer systems. These issues result in low survival rates of probiotics in the gastrointestinal environment and insufficient verification of their anti-inflammatory and intestinal barrier protection effects in vivo.
A bilayer composite microcapsule technology using grape seed polyphenol-metal network and modified starch was adopted. Probiotics were encapsulated in the inner layer of grape seed polyphenol-iron ion metal-phenol network, and the outer layer used mannosylated carboxymethyl starch as the shell. Mannosylated carboxymethyl starch was prepared by amidation-reductive ammoniation reaction to form a dense protective network with pH responsiveness, thus realizing the preparation of bilayer composite microcapsules.
It significantly improved the survival rate of probiotics in a simulated gastrointestinal digestive environment, effectively improved intestinal inflammation and maintained intestinal barrier function. In vitro experiments showed high survival rate of live bacteria, and in vivo experiments showed significant anti-inflammatory and barrier repair effects in a DSS-induced colitis mouse model.
Smart Images

Figure CN123059017A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of microbial microcapsule technology, and relates to a microbial microcapsule based on grape seed polyphenol-metal network and modified starch, its preparation method, and its application in improving intestinal health. Background Technology
[0002] Probiotics are a class of live microorganisms that colonize the human gut and have various beneficial effects on the host's health, including regulating gut microbiota balance, enhancing immune function, and improving the intestinal barrier. *Bifidobacterium longum* subsp. *infantile* (… Bifidobacterium longum subsp. infantis As one of the dominant bacterial species in the gut of infants and adults, probiotics have important application value in maintaining intestinal health and inhibiting the colonization of pathogenic bacteria. However, probiotics face severe challenges in practical applications. After oral administration, they must endure the harsh gastrointestinal environment of stomach acid, bile salts, and digestive enzymes, resulting in the inactivation of a large number of live bacteria and an extremely low effective survival rate upon reaching the intestine, thus severely limiting their physiological functions.
[0003] Although existing microencapsulation technology has improved the survival rate of probiotics to some extent, the following prominent problems still exist: (1) Limited protection of single-layer encapsulation system: Simple alginate or single-layer metal-phenol network and other single-layer structures have limited barrier function in the strongly acidic gastric acid environment, and a large number of live bacteria are inactivated during their stay in the stomach; (2) Poor controllability of intestinal release: Some embedding materials lack response mechanisms for the specific microenvironment of the intestine, making it difficult to achieve effective delivery with stable encapsulation in the stomach and efficient targeted release into the intestine; (3) Insufficient density of traditional starch-based materials: Traditional starch and its simple modified products lack sufficient structural density and synergistic protection mechanism, making it difficult to simultaneously achieve high encapsulation efficiency and tolerance to extreme environments. (4) Existing multilayer systems have complex processes and poor compatibility: Existing composite or multilayer microcapsule preparation processes are cumbersome and costly, or the interlayer materials have poor compatibility, which can easily lead to a significant decrease in encapsulation efficiency or peeling failure.
[0004] (5) Insufficient verification of in vivo anti-inflammatory and intestinal barrier protection effects: Most existing delivery systems only evaluate in vitro survival rates and lack systematic verification of in vivo anti-inflammatory effects and intestinal health-related efficacy.
[0005] Therefore, developing a bilayer composite probiotic microcapsule system that combines high encapsulation efficiency, excellent gastrointestinal protection performance, good biocompatibility, and the ability to effectively improve intestinal inflammation and maintain intestinal barrier function is a technical challenge that urgently needs to be solved in the field of probiotic delivery. Summary of the Invention
[0006] The purpose of this invention is to provide a microbial microcapsule based on grape seed polyphenol-metal network and modified starch.
[0007] Meanwhile, the purpose of this invention is to provide a method for preparing microbial microcapsules based on grape seed polyphenol-metal network and modified starch.
[0008] Meanwhile, the purpose of this invention is to provide an application of microbial microcapsules based on grape seed polyphenol-metal network and modified starch in the preparation of drugs to improve intestinal health.
[0009] To solve the above-mentioned technical problems, the technical solution adopted by the present invention is as follows: A method for preparing microcapsules based on mannosylated carboxymethyl starch-probiotic composite microcapsules (i.e., a method for preparing microbial microcapsules based on grape seed polyphenol-metal network and modified starch) includes the following steps: S1, Preparation of carboxymethyl starch (CMS); S2, Preparation of mannosaccharified carboxymethyl starch (Man-CMS); S3, Preparation of Bifidobacterium longum infant subsp. KEY-1 encapsulated in an inner metal-phenol network (Fe / GSP); S4, Preparation of bilayer composite microcapsules.
[0010] Bifidobacterium longum subspecies infantis KEY-1, Latin name: Bifidobacterium longum subsp infantis KEY-1 is deposited at Guangdong Provincial Center for Microbial Culture Collection, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Province, with accession number GDMCC No: 68845 and deposit date August 17, 2026.
[0011] Bifidobacterium longum infantis subspecies KEY-1 was isolated and purified from infant feces and stored in glycerol tubes at -20°C after collection.
[0012] The isolation, purification, and identification process of Bifidobacterium longum subsp. infantis KEY-1 in this invention is as follows: Take an appropriate amount of infant fecal sample, dilute it with sterile physiological saline, and spread it on MRS agar plates containing L-cysteine hydrochloride. Incubate under anaerobic conditions at 37 °C for 48 h. Select typical round single colonies with smooth surfaces, regular edges, moist and raised, and milky white or grayish white color. After repeated streaking purification, obtain pure cultures (i.e., purified strains).
[0013] The purified bacterial strain was inoculated into MRS solid medium containing L-cysteine hydrochloride and anaerobic incubated at 37 °C for 48 h. Single colonies were selected for Gram staining and observed under a microscope: the strain was Gram-positive, with short rod-shaped or club-shaped cells, arranged singly, in pairs, or in short chains. Some cells showed branching at both ends or exhibited typical "Y", "V", or forked shapes. The ends were blunt and rounded, and there were no spores or flagella.
[0014] PCR amplification and sequencing were performed using universal 16S rRNA primers. The sequencing was completed by Shanghai Sangon Biotech Co., Ltd. Gene sequencing identification and NCBI phylogenetic analysis confirmed that the strain was *Bifidobacterium longum* subsp. *infantitidis*. Bifidobacterium longum subsp. infantis It was named KEY-1. Its 16S rRNA nucleotide sequence is shown in SEQ ID NO. 1.
[0015] The composite microcapsule has KEY-1 encapsulated in an inner layer of grape seed polyphenol-iron ion metal-phenol network (Fe / GSP MPN) as the core and mannosaccharified carboxymethyl starch (Man-CMS) as the shell.
[0016] The bilayer composite microcapsules prepared by the method have high encapsulation efficiency and a significantly better survival rate in a simulated gastrointestinal digestive environment than the KEY-1 group and the single-layer control group.
[0017] The aforementioned mannosylated carboxymethyl starch-probiotic composite microcapsules (i.e., a microbial microcapsule based on grape seed polyphenol-metal network and modified starch) are microcapsule preparations, compound microbial agents, or functional foods.
[0018] Man-CMS is prepared via an amidation-reductive amination reaction, with the inner Fe / GSP network constructed via Fe... 3+ It forms a multi-site coordination with grape seed polyphenols.
[0019] Specifically, a method for preparing microbial microcapsules based on grape seed polyphenol-metal network and modified starch includes the following steps: S1, Preparation of carboxymethyl starch: High amylose corn starch is alkalized and carboxymethylated, then washed and dried to obtain carboxymethyl starch powder; S2, Preparation of mannosaccharified carboxymethyl starch: Carboxymethyl starch is introduced with amino groups through an amidation reaction, and then grafted with D-mannose through a reducing amination reaction to obtain mannosaccharified carboxymethyl starch; S3, Preparation of Bifidobacterium longum infant subsp. KEY-1 embedded in the inner metal-phenol network: After activating Bifidobacterium longum infant subsp. KEY-1, it was mixed with FeCl3 and grape seed polyphenol GSP. Through metal-phenol coordination self-assembly, a monolayer probiotic solution of KEY-1 embedded in the Fe / GSP metal-phenol network was obtained, abbreviated as KEY-1-Fe / GSP. S4, Preparation of bilayer composite microcapsules: The mannosaccharified carboxymethyl starch obtained in step S2 is made into a mannosaccharified carboxymethyl starch suspension receiving liquid. The KEY-1-Fe / GSP from step S3 is added dropwise to the mannosaccharified carboxymethyl starch suspension receiving liquid. After stirring, crosslinking, centrifugation, washing, and freeze-drying, microcapsules based on grape seed polyphenol-metal network and modified starch are obtained.
[0020] Preferably, S1, the preparation of carboxymethyl starch (CMS) yields carboxymethyl starch (CMS) powder; The preparation method of carboxymethyl starch (CMS) includes the following steps: Weigh 10-15 g of high amylose corn starch (Yingjietang brand, manufacturer: LTD) and add it to a three-necked flask containing 90-120 mL of isopropanol solvent. The high amylose corn starch has an amylose content of 55%-70% by mass. Stir at 500-600 rpm and slowly add 12-18 mL of 14.67 mol / L NaOH solution at a rate of 0.5-1.0 mL / min to carry out an alkalization reaction. After stirring and alkalizing for 20 min, add 2.5-3.5 g of chloroacetic acid to the system and heat the system to 35-45℃ for 2-3 h to carry out the carboxymethylation reaction. After the reaction is complete, the product is filtered, the precipitate is suspended in 95% ethanol, and the pH is adjusted to 5.5-6.5 with 50% acetic acid. After filtration again, the precipitate is washed with 85% ethanol until chloride ions are undetectable with 0.1 mol / L silver nitrate. The precipitate is washed 2-3 times with anhydrous ethanol to remove water. The precipitate is dried in an oven at 40-45℃ for 20-30 hours. Finally, the sample is ground into a fine powder and passed through a 60-mesh sieve to obtain the final product.
[0021] Preferably, S2, preparation of mannosylcarboxymethyl starch (Man-CMS): S21, weigh 6-8 g of the prepared carboxymethyl starch (CMS) powder and completely dissolve it in 500 mL of MES buffer. Add 3.0-3.8 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1.8-2.3 g of N-hydroxysuccinimide (NHS) sequentially to the solution for carboxyl activation for 1.5 h. Then, add 18-24 mL of ethylenediamine dropwise to the system, and continue the reaction for 24 h after the addition is complete. After the reaction is complete, transfer the reaction solution to 1 mM HCl solution and dialyze for 24 h, then transfer it to deionized water and dialyze for 48-72 h. Finally, collect the material in the dialysis bag and freeze-dry it to obtain aminoethylated carboxymethyl starch (CMS-NH2).
[0022] More preferably, the method for preparing the MES buffer is as follows: Weigh 39.47 g of 2-(N-morpholino)ethanesulfonic acid (MES) solid into a beaker, add deionized water and stir until completely dissolved, then transfer to a 1 L volumetric flask and make up to volume, and adjust the pH of the system to 5.5 to obtain the MES buffer.
[0023] S22, Preparation of Mannyl Carboxymethyl Starch via Reductive Amination: Weigh all the aminoethylated carboxymethyl starch (CMS-NH2) product obtained in the above steps and completely dissolve it in 300 mL of PBS buffer. Add 12-15 g of D-mannose and 3.5-4 g of reducing agent sodium cyanoborohydride (NaBH3CN) to the solution sequentially to induce a reductive amination reaction between the aldehyde group of D-mannose and the primary amino group at the top of CMS-NH2. Place the reaction system in a sealed environment at 37 ℃ for 48-72 h to allow the reaction products to couple. After the reaction, transfer the entire reaction system to a dialysis bag and dialyze with ultrapure water for 72 h to remove unreacted small molecule impurities. After dialysis, collect the material in the dialysis bag and freeze-dry it to obtain the final mannyl carboxymethyl starch (Man-CMS).
[0024] More preferably, the preparation method of phosphate (PBS) buffer is as follows: commercial PBS tablets (product number Top1010, manufacturer: Beijing Boao Tuoda Technology Co., Ltd., one bag of dry powder can prepare 2L of standard 0.01M PBS buffer, the dry powder addition mass is 20g / bag) are completely dissolved in 2L of ultrapure water and mixed evenly for later use.
[0025] Preferably, S3, preparation of Bifidobacterium infantis embedded in the inner metal-phenol network: S31, activate Bifidobacterium longum subsp. infantis KEY-1 to obtain activated bacterial solution of Bifidobacterium longum subsp. infantis KEY-1; First, the cryopreserved *Bifidobacterium longum* subsp. *infantii* (KEY-1) strain was removed from a -20 °C constant temperature environment and thawed at -4 °C. The thawed bacterial culture was inoculated into MRS liquid medium containing L-cysteine hydrochloride at a 2% volume inoculum and anaerobically cultured at 37 °C for 48 h to complete the first generation activation. Then, it was transferred to the same medium at a 2% volume inoculum and cultured for 24 h to complete the second generation activation. This process was repeated to subculture to the third generation to obtain the third generation KEY-1 activated bacterial culture with optimal activity.
[0026] More preferably, the MRS broth medium (i.e., MRS liquid medium containing L-cysteine hydrochloride) comprises: 5.0 g peptone, 10.0 g tryptone, 5.0 g sodium acetate, 2.0 g dipotassium hydrogen phosphate, 20.0 g glucose, 5.0 g yeast extract, 0.25 g manganese sulfate, 0.58 g magnesium sulfate, 2.0 g diammonium hydrogen citrate, 1.0 g Tween-80, 5.0 g beef extract, and 0.5 g L-cysteine hydrochloride. These are dissolved in distilled water and brought to a final volume of 1 L. The mixture is stirred thoroughly and sterilized at 121°C for 15 min. The temperature is 37°C.
[0027] S32, take 1 mL of third-generation KEY-1 activated bacterial solution (1×10⁻⁶) 9 The bacterial suspension was then resuspended in 1 mL of sterile phosphate (PBS) buffer to obtain the KEY-1 bacterial suspension (bacterial concentration approximately 1 × 10⁻⁶ CFU / mL). 9 CFU / mL). That is: take 1 mL of bacteria with a concentration of 1×10⁻⁶. 9 The activated bacterial suspension of third-generation Bifidobacterium longum subsp. infantis KEY-1 (CFU / mL) was centrifuged to collect the bacterial cells. After discarding the supernatant, the suspension was resuspended in 1 mL of PBS buffer to obtain the KEY-1 bacterial suspension. The bacterial concentration of the KEY-1 suspension was 1 × 10⁻⁶. 9 CFU / mL. Prepare a 5 mg / mL FeCl3 solution and a 20 mg / mL grape seed polyphenol (GSP) solution separately. Take 100 μL of the above KEY-1 bacterial suspension and mix it with 880 μL of PBS buffer. Then, slowly add 10 μL of FeCl3 solution and 10 μL of GSP solution dropwise at a rate of 0.5–1.0 mL / min, respectively, to adjust the Fe concentration in the system. 3+ The mass ratio of GSP to bacterial suspension was 2.5:10:1. After the sample was added, it was mixed at room temperature for 20 min to obtain 1 mL of KEY-1 monolayer probiotic solution embedded in Fe / GSP metal-phenol network (hereinafter referred to as KEY-1-Fe / GSP).
[0028] Preferably, S4, preparation of bilayer composite microcapsules: S41, firstly, the mannosylcarboxymethyl starch (Man-CMS) matrix obtained in step S2 is completely dissolved in ultrapure water to prepare a 1% (w / w) Man-CMS suspension receiving solution. The 1% Man-CMS suspension receiving solution is placed on a magnetic stirrer, and the stirring speed is controlled at 300-500 rpm. Then, the KEY-1-Fe / GSP monolayer encapsulated probiotic suspension prepared in step S3 is loaded into a syringe and precisely controlled using a JSPA / B series high-precision split-type syringe pump to drip into the 1% Man-CMS suspension receiving solution at a constant flow rate of 200 μL / min through a coaxial microneedle. The volume ratio of the KEY-1-Fe / GSP monolayer encapsulated probiotic suspension to the Man-CMS suspension receiving solution is controlled to be approximately 1:8-1:12.
[0029] S42, after the addition was complete, was reacted continuously for 30 minutes at room temperature and with stirring at 600 rpm. During this process, the iron ions in the inner layer coordinated and crosslinked with the carboxyl groups on the outer Man-CMS molecular chain, and synergistically formed electrostatic interactions and hydrogen bonds, driving the shell material to self-assemble on the core surface, thereby forming a structurally complete bilayer core-shell microcapsule. After the reaction was completed, the resulting mixture was transferred to a centrifuge tube and centrifuged at 3000-5000 rpm for 5 minutes to collect the microcapsule precipitate. The supernatant was discarded, and the precipitate was washed 2-3 times with deionized water to remove any remaining free fractions on the surface. Finally, the washed precipitate was placed in a freeze dryer for vacuum freeze-drying to obtain the final KEY-1 / GM-CMS bilayer composite microcapsule solid powder.
[0030] More preferably, the specific process parameters for vacuum freeze-drying are as follows: pre-freezing at -80℃ for 10-15 hours; maintaining the cold trap temperature at -60℃ and the vacuum pressure at 5-20 Pa; during the main drying stage, the sample temperature is gradually increased from -40℃ to -20℃ for 20-30 hours; during the secondary drying stage, the sample temperature is slowly increased from -20℃ to 20-25℃ for 6-12 hours until the sample moisture content is below 5%. After freeze-drying, the gas inlet is slowly opened, and the sample is removed after waiting 4-5 minutes.
[0031] The microbial microcapsules based on grape seed polyphenol-metal network and modified starch obtained in this invention have an encapsulation efficiency of 82.5-83.4% and a viable bacterial count after simulated gastrointestinal digestion of 8.15-8.23 log after 2 hours of simulated gastric juice digestion. 10 After CFU / mL, simulated intestinal digestion for 4 hours (i.e., simulated gastric digestion for 2 hours + simulated intestinal digestion for 4 hours, i.e., total digestion for 6 hours), the viable bacterial count was 7.72-7.81 log. 10 CFU / mL.
[0032] The present invention relates to the application of microbial microcapsules based on grape seed polyphenol-metal network and modified starch in improving gut health.
[0033] The application of the microbial microcapsules based on grape seed polyphenol-metal network and modified starch obtained in this invention in the preparation of drugs to improve intestinal health.
[0034] Medicines that improve gut health include those that improve gut inflammation and maintain intestinal barrier function.
[0035] The application of the microbial microcapsules based on grape seed polyphenol-metal network and modified starch obtained in this invention in microcapsule formulations, compound microbial agents or functional foods.
[0036] To improve the gastrointestinal tolerance of probiotics, microencapsulation technology has been widely studied and applied. Commonly used encapsulation materials include alginate, chitosan, protein, starch, and its derivatives. Among these, carboxymethyl starch (CMS) has become an important candidate material for probiotic carriers due to its good water solubility, biocompatibility, and biodegradability. This invention further chemically modifies CMS to impart pH responsiveness and potential targeted adhesion capabilities. On the other hand, the metal-phenolic networks (MPNs) of this invention, formed by metal ions and polyphenolic compounds through multi-site coordination and hydrogen bonding, exhibit excellent biocompatibility, antioxidant capacity, and protective effects against microorganisms.
[0037] Compared with the prior art, the present invention has the following beneficial effects: This invention discloses a microbial microcapsule based on a grape seed polyphenol-metal network and modified starch, its preparation method, and its application in improving gut health, belonging to the field of probiotic microcapsule formulation technology. The composite microcapsule uses an inner layer of grape seed polyphenol-iron ion metal-phenol network (Fe-GSP) encapsulating Bifidobacterium infantis (KEY-1) as the core, and a shell of mannosylcarboxymethyl starch (Man-CMS) prepared by an amidation-reductive ammoniation reaction. This invention uses steps S1-S4 to prepare the bilayer microcapsule, through the inner Fe... 3+ The dual-layer microcapsules, through multi-site coordination with GSP to form a dense protective network and the pH-responsive carboxyl group of the outer Man-CMS layer, significantly improved the tolerance of KEY-1 to simulated gastrointestinal fluid. In vitro evaluation results showed that the viable bacterial survival rate of this dual-layer microcapsule in simulated gastrointestinal digestion experiments was significantly better than that of the KEY-1 group and the single-layer control group. Furthermore, animal experiments demonstrated that the dual-layer microcapsules of this invention, in a DSS-induced colitis mouse model, effectively alleviated weight loss, reduced the disease activity index (DAI), improved colonic shortening, reduced colonic tissue pathological damage, and upregulated the mRNA expression levels of tight junction proteins Occludin and ZO-1, exhibiting effects in improving intestinal inflammation and maintaining intestinal barrier function. This invention, through the strong protection of the metallophenol coordination network and the synergistic effect of the pH-responsive mannosylated carboxymethyl starch, enhances the survival rate of probiotics in a simulated gastrointestinal digestive environment and verifies its ability to improve intestinal inflammation and promote intestinal barrier repair in vivo, solving the problems of easy large-scale inactivation in the gastrointestinal tract and insufficient in vivo efficacy verification of traditional delivery systems. Attached Figure Description
[0038] Figure 1 A comparison of the appearance of carboxymethyl starch and high amylose corn starch when dissolved in water; Figure 2Scanning electron microscope images of high amylose corn starch, CMS, and Man-CMS, among which... A is a scanning electron microscope image of high amylose corn starch; B is a scanning electron microscope image of CMS; C is a scanning electron microscope image of Man-CMS. Figure 3 Fourier transform infrared spectra of high amylose corn starch, CMS, and Man-CMS; Figure 4 This is a transmission electron microscope image of KEY-1 naked bacteria; Figure 5 This is a transmission electron microscope image of a single-layer microcapsule; Figure 6 Transmission electron microscope image of bilayer microcapsules Figure 7 The diagrams show the particle size and zeta potential of the bilayer microcapsules, where (A) is the particle size diagram and (B) is the zeta potential diagram. Figure 8 A graph showing the encapsulation efficiency of double-layer microcapsules; Figure 9 A simulated gastrointestinal digestion diagram for naked bacteria, single-layer, and double-layer microcapsules; Figure 10 A comparison chart of encapsulation efficiency for different inner layer embedding systems; Figure 11 A graph showing the percentage of body weight in different groups of mice with colitis; Figure 12 A graph showing the disease activity evaluation index of different groups of colitis mice; Figure 13 The images show colonic images and colonic length images of different groups of mice with colitis. In the image, A shows the colonic image of different groups of mice with colitis, and B shows the colonic length image. Figure 14 HE staining images of colon tissue sections from different groups; Figure 15 The graph shows the mRNA expression levels of ZO-1 and Occludin in different groups. Detailed Implementation
[0039] The present invention will be further described below with reference to the accompanying drawings and embodiments, but the present invention is not limited to the following embodiments. Unless otherwise specified, the raw materials used in the embodiments can be obtained through conventional commercial means, and the methods used are conventional methods in the art.
[0040] Example 1 This embodiment provides a microbial microcapsule based on grape seed polyphenol-metal network and modified starch, wherein the inner layer of grape seed polyphenol-iron ion metal-phenol network (Fe / GSP) encapsulates Bifidobacterium longum subsp. infantis. Bifidobacterium longum subsp. infantis A bilayer composite microcapsule with KEY-1 as the core and mannosylcarboxymethyl starch (Man-CMS) as the shell. The grape seed polyphenol-metal network is specifically a grape seed proanthocyanidin-iron ion self-assembly network, and the mannosylcarboxymethyl starch is specifically α-D-mannopyranose-modified carboxymethyl starch.
[0041] Bifidobacterium longum subspecies infancy KEY-1 is deposited at the Guangdong Provincial Culture Collection Center for Microbial Culture, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Province, with accession number GDMCC No: 68845 and deposit date of August 17, 2026. This strain was isolated from fecal samples of healthy breastfed full-term infants in Heilongjiang Province and stored in glycerol tubes at -20 ℃ after collection.
[0042] A method for preparing microbial microcapsules based on structurally characteristic grape seed polyphenol-metal network and modified starch includes the following steps: S1, Preparation of carboxymethyl starch (CMS): 12 g of high amylose corn starch (Yingjietang brand, manufacturer: LTD) was weighed and added to a three-necked flask containing 108 mL of isopropanol solvent. The high amylose corn starch had an amylose content of 65% by mass. The mixture was stirred at 550 rpm, and 15 mL of 14.67 mol / L NaOH solution was slowly added dropwise at a rate of 0.8 mL / min to initiate an alkalization reaction. After alkalization for 20 min, 2.8 g of chloroacetic acid was added to the system, and the temperature was raised to 40 °C for 2.5 h to initiate a carboxymethylation reaction. After the reaction was completed, the product was filtered, the precipitate was suspended in 95% ethanol, and the pH was adjusted to 6.0 with 50% acetic acid. After filtration again, the precipitate was washed with 85% ethanol until chloride ions were undetectable with 0.1 mol / L silver nitrate. The precipitate was washed twice with anhydrous ethanol to remove water, and then dried in an oven at 45°C for 24 h. Finally, the sample was ground into a fine powder and passed through a 60-mesh sieve to obtain carboxymethyl starch (CMS) powder.
[0043] S2, Preparation of mannosyl carboxymethyl starch (Man-CMS): First, prepare the MES buffer: Weigh 39.47 g of 2-(N-morpholino)ethanesulfonic acid (MES) solid into a beaker, add deionized water and stir until completely dissolved. Then transfer to a 1 L volumetric flask and make up to volume, adjusting the pH of the system to 5.5 to obtain the MES buffer. Next, weigh 7 g of the prepared carboxymethyl starch (CMS) powder and dissolve it completely in 500 mL of the MES buffer. Add 3.36 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 2.03 g of N-hydroxysuccinimide (NHS) sequentially to the solution for carboxyl activation for 1.5 h. Then, add 21 mL of ethylenediamine dropwise to the system, and continue the reaction for 24 h after the addition is complete. After the reaction was completed, the reaction solution was transferred to 1 mM HCl solution for dialysis for 24 h, then transferred to deionized water for dialysis for 60 h. Finally, the substance in the dialysis bag was collected and freeze-dried to obtain aminoethylated carboxymethyl starch (CMS-NH2).
[0044] Preparation of Mannyl Carboxymethyl Starch via Reductive Amination: First, prepare a phosphate-buffered saline (PBS) buffer: Dissolve commercial PBS tablets completely in 2 L of ultrapure water and mix thoroughly. Then, weigh all the aminoethylated carboxymethyl starch (CMS-NH2) product obtained in the previous step and dissolve it completely in 300 mL of the PBS buffer. Add 13.5 g of D-mannose and 3.75 g of reducing agent sodium cyanoborohydride (NaBH3CN) sequentially to the solution to induce a reductive amination reaction between the aldehyde group of D-mannose and the primary amino group at the top of CMS-NH2. The reaction system is kept in a sealed environment at 37 °C for 60 h to allow the reaction products to couple. After the reaction, transfer the entire reaction system to a dialysis bag and dialyze with ultrapure water for 72 h to remove unreacted small molecule impurities. After dialysis, collect the contents of the dialysis bag and freeze-dry to obtain the final mannyl carboxymethyl starch (Man-CMS).
[0045] S3, Preparation of Bifidobacterium infantis embedded in the inner metal-phenol network: Bifidobacterium longum subspecies infantis KEY-1, Latin name: Bifidobacterium longum subsp infantis KEY-1 is deposited at Guangdong Provincial Center for Microbial Culture Collection, accession number GDMCC No: 68845, deposited on August 17, 2026.
[0046] First, the cryopreserved *Bifidobacterium longum* subsp. *infantii* (KEY-1) strain was removed from a -20 °C constant temperature environment and thawed at -4 °C. The thawed bacterial culture was inoculated into MRS liquid medium containing L-cysteine hydrochloride at a 2% volume inoculum and anaerobically cultured at 37 °C for 48 h to complete the first generation activation. Then, it was transferred to the same medium at a 2% volume inoculum and cultured for 24 h to complete the second generation activation. This process was repeated to subculture to the third generation to obtain the third generation KEY-1 activated bacterial culture with optimal activity.
[0047] The MRS broth medium (i.e., MRS liquid medium containing L-cysteine hydrochloride) consists of the following components: 5.0 g peptone, 10.0 g tryptone, 5.0 g sodium acetate, 2.0 g dipotassium hydrogen phosphate, 20.0 g glucose, 5.0 g yeast extract, 0.25 g manganese sulfate, 0.58 g magnesium sulfate, 2.0 g diammonium citrate, 1.0 g Tween-80, 5.0 g beef extract, and 0.5 g L-cysteine hydrochloride. Dissolve these components in distilled water and bring the volume to 1 L. Stir well and sterilize at 121°C for 15 min. Temperature: 37°C.
[0048] Take 1 mL of third-generation KEY-1 activated bacterial solution (1×10⁻⁶) 9 The bacterial suspension was then resuspended in 1 mL of sterile phosphate (PBS) buffer to obtain the KEY-1 bacterial suspension (bacterial concentration approximately 1 × 10⁻⁶ CFU / mL). 9 (CFU / mL). Prepare a 5 mg / mL FeCl3 metal ion solution and a 20 mg / mL grape seed polyphenol (GSP) solution (McKalin brand, catalog number G832674). Transfer 10 μL of the FeCl3 metal ion solution and 10 μL of the grape seed polyphenol (GSP) solution to a mixture containing 880 μL of PBS buffer and 100 μL of KEY-1 bacterial suspension at a rate of 0.8 mL / min. 3+ The mass ratio of ions, grape seed polyphenols, and bacterial suspension was 2.5:10:1. After sample addition, the mixture was stirred at room temperature for 20 min. Through the self-assembly of metal ions and polyphenols at multiple sites, a dense network was formed on the surface of the bacterial cells, ultimately yielding a 1 ml system of KEY-1-Fe / GSP monolayer encapsulated probiotic suspension.
[0049] S4, Preparation of bilayer composite microcapsules: First, the mannosylcarboxymethyl starch (Man-CMS) matrix obtained in step S2 was completely dissolved in ultrapure water to prepare a 1% (w / w) Man-CMS suspension. The 1% Man-CMS suspension was placed on a magnetic stirrer and the stirring speed was controlled at 400 rpm. Then, the KEY-1-Fe / GSP monolayer encapsulated probiotic suspension prepared in step S3 was loaded into a syringe and precisely controlled using a JSPA / B series high-precision split-type syringe pump to drip into the 1% Man-CMS suspension at a constant flow rate of 200 μL / min through a coaxial microneedle. The volume ratio of the KEY-1-Fe / GSP monolayer encapsulated probiotic suspension to the Man-CMS suspension was controlled to be approximately 1:10.
[0050] After the addition was complete, the reaction was continued for 30 minutes at room temperature and with stirring at 600 rpm. During this process, the iron ions in the inner layer coordinated and crosslinked with the carboxyl groups on the outer Man-CMS molecular chain, and synergistically formed electrostatic interactions and hydrogen bonds, driving the shell material to self-assemble on the core surface, thereby forming a structurally complete bilayer core-shell microcapsule. After the reaction was completed, the resulting mixture was transferred to a centrifuge tube and centrifuged at 4000 rpm for 5 minutes to collect the microcapsule precipitate. The supernatant was discarded, and the precipitate was washed twice with deionized water to remove any remaining free fractions on the surface. Finally, the washed precipitate was placed in a freeze dryer for vacuum freeze-drying to obtain the final KEY-1 / GM-CMS bilayer composite microcapsule solid powder. The KEY-1 / GM-CMS bilayer composite microcapsule has a core of KEY-1 encapsulated in an inner grape seed polyphenol-iron ion metal-phenol network (Fe / GSP MPN) and a shell of mannosylcarboxymethyl starch (Man-CMS).
[0051] The specific process parameters for vacuum freeze-drying are as follows: pre-freezing at -80℃ for 12 h; maintaining the cold trap temperature at -60℃ and the vacuum pressure at 5 Pa; during the main drying stage, the sample temperature is gradually increased from -40℃ to -20℃ and maintained for 24 h; during the secondary drying stage, the sample temperature is slowly increased from -20℃ to 22℃ and maintained for 10 h, until the sample moisture content is below 5%. After freeze-drying, the gas inlet is slowly opened, and the sample is removed after waiting for 4.5 min.
[0052] The encapsulation efficiency of KEY-1-Fe / GSP MPN-Man-CMS obtained in this embodiment was 83%. The viable bacterial count after simulated gastrointestinal digestion was 8.20 log after 2 hours of SGF treatment. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 7.79 log. 10 CFU / mL.
[0053] The application of microbial microcapsules based on grape seed polyphenol-metal network and modified starch obtained in this embodiment to improve gut health.
[0054] The application of the microbial microcapsules based on grape seed polyphenol-metal network and modified starch obtained in this embodiment in the preparation of drugs to improve intestinal health.
[0055] Medicines that improve gut health include those that improve gut inflammation and maintain intestinal barrier function.
[0056] Example 2 The only difference between this embodiment and Embodiment 1 is that: S1, Preparation of carboxymethyl starch (CMS): 10 g of high amylose corn starch was weighed and added to a three-necked flask containing 90 mL of isopropanol solvent. The high amylose corn starch had an amylose content of 55% by mass. The mixture was stirred at 500 rpm, and 12 mL of 14.67 mol / L NaOH solution was slowly added dropwise at a rate of 0.5 mL / min for alkalization. After alkalization for 20 min, 2.5 g of chloroacetic acid was added to the system, and the temperature was raised to 35 °C for 2 h to carry out carboxymethylation. After the reaction, the product was filtered, and the precipitate was suspended in 95% ethanol. The pH was adjusted to 5.5 with 50% acetic acid, filtered again, and the precipitate was washed with 85% ethanol until chloride ions were undetectable with 0.1 mol / L silver nitrate. The precipitate was washed three times with anhydrous ethanol for dehydration, and then dried in an oven at 40 °C for 20 h. Finally, the sample was ground into a fine powder and passed through a 60-mesh sieve to obtain carboxymethyl starch (CMS) powder.
[0057] S2, Preparation of mannosyl carboxymethyl starch (Man-CMS): 6 g of the prepared carboxymethyl starch (CMS) powder was weighed and completely dissolved in 500 mL of MES buffer. 3.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1.8 g of N-hydroxysuccinimide (NHS) were added sequentially to the solution for carboxyl activation for 1.5 h. Subsequently, 18 mL of ethylenediamine was added dropwise, and the reaction continued for 24 h after the addition was complete. After the reaction was completed, the reaction solution was transferred to 1 mM HCl solution and dialyzed for 24 h, then transferred to deionized water and dialyzed for 48 h. Finally, the substance in the dialysis bag was collected and freeze-dried to obtain aminoethylated carboxymethyl starch (CMS-NH2).
[0058] S22, Preparation of mannosylated carboxymethyl starch by reducing amination reaction: Weigh all the aminoethylated carboxymethyl starch (CMS-NH2) product obtained in the above steps, and completely dissolve it in 300 mL PBS buffer. Add 12 g of D-mannose and 3.5 g of reducing agent sodium cyanoborohydride (NaBH3CN) to the solution sequentially. Place the reaction system in a sealed environment at 37 ℃ for 48 h.
[0059] S3, Preparation of Bifidobacterium infantis embedded in the inner metal-phenol network: Preparation of Fe 3+ When adding ions, grape seed polyphenols, and bacterial suspension, add slowly at a rate of 0.5 mL / min.
[0060] S4, Preparation of bilayer composite microcapsules: The stirring speed of the magnetic stirrer is 300 rpm. The volume ratio of the KEY-1-Fe / GSP monolayer encapsulated probiotic suspension to the Man-CMS suspension receiving liquid is approximately 1:8.
[0061] After the reaction was complete, the resulting mixture was transferred to a centrifuge tube and centrifuged at 3000 rpm for 5 min to collect the microcapsule precipitate. The supernatant was discarded, and the precipitate was washed three times with deionized water to remove any remaining free fractions on the surface. Finally, the washed precipitate was placed in a freeze dryer for vacuum freeze-drying to obtain the final KEY-1 / GM-CMS bilayer composite microcapsule solid powder.
[0062] The specific process parameters for vacuum freeze-drying are as follows: pre-freezing at -80℃ for 10 h; maintaining the cold trap temperature at -60℃ and the vacuum pressure at 20 Pa; during the main drying stage, the sample temperature is gradually increased from -40℃ to -20℃ and maintained for 20 h; during the secondary drying stage, the sample temperature is slowly increased from -20℃ to 20℃ and maintained for 6 h, until the sample moisture content is below 5%. After freeze-drying, the gas inlet is slowly opened, and the sample is removed after waiting for 4 minutes.
[0063] The KEY-1 / GM-CMS bilayer composite microcapsules prepared in this embodiment had an encapsulation efficiency of 82.5%. Simulated gastrointestinal digestion viable bacterial count: 8.15 log₂SGF viable bacterial count after 2 hours. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 7.72 log. 10 CFU / mL.
[0064] Example 3 The only difference between this embodiment and Embodiment 1 is that: S1, Preparation of carboxymethyl starch (CMS): 15 g of high amylose corn starch was weighed and added to a three-necked flask containing 120 mL of isopropanol solvent. The high amylose corn starch contained 70% amylose by mass. The mixture was stirred at 600 rpm, and 18 mL of 14.67 mol / L NaOH solution was slowly added dropwise at a rate of 1.0 mL / min for alkalization. After alkalization for 20 min, 3.5 g of chloroacetic acid was added to the system, and the temperature was raised to 45 °C for 3 h to carry out carboxymethylation. After the reaction, the product was filtered, and the precipitate was suspended in 95% ethanol. The pH was adjusted to 6.5 with 50% acetic acid, filtered again, and the precipitate was washed with 85% ethanol until chloride ions were undetectable with 0.1 mol / L silver nitrate. The precipitate was washed three times with anhydrous ethanol for dehydration, and then dried in an oven at 45 °C for 30 h. Finally, the sample was ground into a fine powder and passed through a 60-mesh sieve to obtain carboxymethyl starch (CMS) powder.
[0065] S2, Preparation of mannosyl carboxymethyl starch (Man-CMS): 8 g of the prepared carboxymethyl starch (CMS) powder was weighed and completely dissolved in 500 mL of MES buffer. 3.8 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 2.3 g of N-hydroxysuccinimide (NHS) were added sequentially to the solution for carboxyl activation for 1.5 h. Subsequently, 24 mL of ethylenediamine was added dropwise to the system, and the reaction continued for 24 h after the addition was complete. After the reaction was completed, the reaction solution was transferred to 1 mM HCl solution and dialyzed for 24 h, then transferred to deionized water and dialyzed for 72 h. Finally, the substance in the dialysis bag was collected and freeze-dried to obtain aminoethylated carboxymethyl starch (CMS-NH2).
[0066] Preparation of mannosylated carboxymethyl starch by reductive amination: Weigh all the aminoethylated carboxymethyl starch (CMS-NH2) product obtained in the above steps and completely dissolve it in 300 mL of PBS buffer. Add 15 g of D-mannose and 4 g of reducing agent sodium cyanoborohydride (NaBH3CN) to the solution sequentially. Place the reaction system in a sealed environment at 37 ℃ for 72 h.
[0067] S3, Preparation of Bifidobacterium infantis embedded in the inner metal-phenol network: Preparation of Fe 3+ When adding ions, grape seed polyphenols, and bacterial suspension, add slowly at a rate of 1.0 mL / min.
[0068] S4, Preparation of bilayer composite microcapsules: The stirring speed of the magnetic stirrer is 500 rpm. The volume ratio of the KEY-1-Fe / GSP monolayer encapsulated probiotic suspension to the Man-CMS suspension receiving liquid is approximately 1:12.
[0069] After the reaction was completed, the resulting mixture was transferred to a centrifuge tube and centrifuged at 5000 rpm for 5 min to collect the microcapsule precipitate. The supernatant was discarded, and the precipitate was washed three times with deionized water to remove any remaining free fractions on the surface. Finally, the washed precipitate was placed in a freeze dryer for vacuum freeze-drying to obtain the final KEY-1 / GM-CMS bilayer composite microcapsule solid powder.
[0070] The specific process parameters for vacuum freeze-drying are as follows: pre-freezing at -80℃ for 15 h; maintaining the cold trap temperature at -60℃ and the vacuum pressure at 10 Pa; during the main drying stage, the sample temperature is gradually increased from -40℃ to -20℃ and maintained for 30 h; during the secondary drying stage, the sample temperature is slowly increased from -20℃ to 25℃ and maintained for 12 h, until the sample moisture content is below 5%. After freeze-drying, the gas inlet is slowly opened, and the sample is removed after waiting for 5 min.
[0071] The KEY-1 / GM-CMS bilayer composite microcapsules prepared in this embodiment had an encapsulation efficiency of 83.4%. Simulated gastrointestinal digestion viable bacterial count: 8.23 log [value missing] after 2 hours of SGF treatment. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 7.81 log. 10 CFU / mL.
[0072] Comparative Example The present invention also prepared control groups such as KEY-1-Fe, KEY-1-GSP, KEY-1-Fe / EGCG, KEY-1-Fe / AP, and KEY-1-Ca / GSP. The encapsulation efficiency and gastrointestinal survival rate were significantly lower than those of the bilayer system of the present invention, which confirmed the superiority of the synergy between KEY-1 / Fe-GSP and Man-CMS.
[0073] The KEY-1-Fe control group was prepared by treating the KEY-1 bacterial suspension with FeCl3 solution only, without adding grape seed polyphenols; the remaining steps were the same as S3 in Example 1. Encapsulation efficiency: 61.5%. Viable bacterial count after simulated gastrointestinal digestion: 6.85 log [value missing] after 2 h of SGF treatment. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 5.92 log. 10 CFU / mL.
[0074] The KEY-1-GSP control group was prepared by treating the KEY-1 bacterial suspension with only grape seed polyphenol solution, without adding FeCl3, and the remaining steps were the same as S3 in Example 1. Encapsulation efficiency: 58.2%. Viable bacterial count after simulated gastrointestinal digestion: 6.72 log after 2 h of SGF treatment. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 5.68 log. 10 CFU / mL.
[0075] The KEY-1-Fe / EGCG control group was prepared by replacing grape seed polyphenols with epigallocatechin gallate (EGCG), with the remaining steps the same as S3 in Example 1. Encapsulation efficiency: 75.8%. Viable bacterial count after simulated gastrointestinal digestion: 7.15 log after 2 h of SGF2. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 6.35 log. 10 CFU / mL.
[0076] The KEY-1-Fe / AP control group was prepared by replacing grape seed polyphenols with apple polyphenols (AP), with the remaining steps the same as S3 in Example 1. Encapsulation efficiency: 68.4%. Viable bacterial count after simulated gastrointestinal digestion: 6.98 log [value missing] after 2 h of SGF. 10 CFU / ml, viable count after 6 h of total digestion was 6.10 log. 10 CFU / ml.
[0077] The KEY-1-Ca / GSP control group was prepared by replacing FeCl3 with CaCl2, with the remaining steps the same as S3 in Example 1. Encapsulation efficiency: 53.9%. Viable bacterial count after simulated gastrointestinal digestion: 6.45 log [value missing] after 2 h of SGF. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 5.40 log. 10 CFU / mL.
[0078] The preparation method of the KEY-1-Fe / GSP MPN-CMS control group was as follows: the inner layer was prepared as in S3 of Example 1, using KEY-1-Fe / GSP; the outer layer used unmodified carboxymethyl starch (CMS) instead of Man-CMS; the remaining steps were the same as in S4 of Example 1. Encapsulation efficiency: 78.6%. Viable bacterial count after simulated gastrointestinal digestion: 7.45 log after 2 h of SGF. 10 CFU / mL, viable count after 6 h of total digestion was 6.82 log. 10 CFU / mL.
[0079] The preparation method of the KEY-1-Fe / GSP MPN-CMS-NH2 control group was as follows: the inner layer was the same as S3 in Example 1, and the outer layer used aminoethylated carboxymethyl starch (CMS-NH2) instead of Man-CMS. The remaining steps were the same as S4 in Example 1. Encapsulation efficiency: 80.2%. Viable bacteria count after simulated gastrointestinal digestion: 7.58 log after 2 h of SGF. 10 CFU / mL, total viable bacterial count after 6 h of digestion was 6.95 log. 10 CFU / mL.
[0080] The difference between this KEY-1-Fe / GSP MPN-CMS-NH2 control group and the aforementioned KEY-1-Fe control group is that the KEY-1-Fe control group only contains iron ions, without polyphenols or a shell; the KEY-1-Fe / GSP MPN-CMS-NH2 control group has a complete Fe / GSP inner network and a shell, but the shell is not attached to mannose.
[0081] The preparation method of the KEY-1-Fe-Man-CMS control group was as follows: the only difference from Example 1 was that KEY-1 was directly coated with Man-CMS after being treated with FeCl3, without the addition of grape seed polyphenols. Encapsulation efficiency: 72.5%. Viable bacteria count after simulated gastrointestinal digestion: 7.10 log after 2 h of SGF treatment. 10 CFU / mL, viable bacterial count after 6 h of total digestion was 6.25 log. 10 CFU / mL.
[0082] The preparation method of the KEY-1-GSP-Man-CMS control group was as follows: the only difference from Example 1 was that KEY-1 was directly coated with Man-CMS after treatment with grape seed polyphenols, without the addition of FeCl3. Encapsulation efficiency: 70.8%. Viable bacteria count after simulated gastrointestinal digestion: 6.95 log after 2 h of SGF treatment. 10 CFU / mL, viable count after 6 h of total digestion was 6.15 log. 10 CFU / mL.
[0083] Characterization methods: Fourier transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), particle size and zeta potential were used to characterize the bilayer microcapsules.
[0084] Encapsulation efficiency of double-layer microcapsules: 1 mL of the prepared microcapsules were dissolved in 9 mL of physiological saline and homogenized at 6000 rpm for 2 minutes. The bacterial suspension was serially diluted and spread onto MRS agar plates, and anaerobically incubated at 37°C for 48 h for viable cell counting.
[0085] Encapsulation efficiency is calculated using the formula: Encapsulation rate (%) =N 1 / N .
[0086] in N 1 represents the number of viable bacteria after packaging. N Represents the initial number of live bacteria added before packaging ( Figure 8 ).
[0087] In vitro simulated gastrointestinal digestion evaluation method: Simulated gastric juice (SGF, pH 2.0, containing pepsin) and simulated intestinal juice (SIF, pH 6.8, containing trypsin and bile salts) were prepared separately. KEY-1 / GM-CMS (i.e., KEY-1 / GM-CMS bilayer composite microcapsule solid powder) and other examples and comparative examples were incubated in SGF for 2 h, and then 100 μL of samples were immediately taken, serially diluted, and plated on MRS agar plates containing cysteine. After anaerobic incubation at 37℃ for 48 h, the viable bacterial count was counted. Subsequently, all samples treated with SGF for 2 h were transferred to SIF and incubated at 37℃ for another 4 h. 100 μL of samples were taken again after transfer, and the same method was used for dilution, plate plating, and counting. Figure 9 ).
[0088] Mechanism Explanation: The bilayer microcapsule of this invention uses an inner layer of grape seed polyphenol-iron ion metal-phenol network (Fe / GSPMPN) encapsulating Bifidobacterium longum subsp. infantis KEY-1 as the core, and an outer layer of mannosylcarboxymethyl starch (Man-CMS) as the shell. Through a pH-responsive release and MPN protection-adhesion synergistic mechanism, it achieves effective protection of probiotics in the gastrointestinal tract. The carboxymethyl groups in the outer Man-CMS are protonated in the acidic environment of the stomach, causing the molecular chain to contract and acting as a physical barrier; in the weakly alkaline environment of the colon (pH 6.8-7.4), the carboxyl groups are deprotonated, leading to swelling, and are simultaneously specifically degraded by α-amylase and β-glucosidase secreted by colonic microorganisms, releasing the inner layer structure. The inner Fe / GSP MPN then releases the probiotics through the Fe... 3+ It coordinates with multiple catechol groups in GSP at multiple sites, forming a dense network through hydrogen bonding, π-π stacking, and hydrophobic interactions. The synergistic effect of these two mechanisms effectively solves the problem of traditional probiotic delivery systems being intolerant to gastric acid and the intestinal environment. Through the pH-responsive barrier of the outer shell and the strong coordination protection mechanism of the inner core, it improves the survival rate of probiotics in simulated gastrointestinal digestion processes, demonstrating good barrier and protective efficacy.
[0089] 1. Animal Experiment Design SPF-grade C57BL / 6 mice were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The mice were 6-8 weeks old at the time of purchase. The animals were housed in an SPF-grade barrier environment using a filtered, independently ventilated cage system with a 12h / 12h light / dark cycle, a temperature controlled at 22±2℃, and a relative humidity of 45±10%. All feed and bedding used in the experiment were purchased from the same company.
[0090] Before the experiment, mice were given free access to food and water. After one week of acclimatization, they were randomly divided into 5 groups of 8 mice each, for a total of 40 mice, based on the principle that there was no significant difference in average body weight among the groups. These groups were the normal control group (NC), the model group (MC), the KEY-1 group, the KEY-1-Fe / GSP group, and the KEY-1 / GM-CMS group. The formal experiment began on day 0. Days 0-7 were the pretreatment phase, and the daily gavage solutions for each group are shown in Table 1 below. Days 8-14 were the DSS induction phase. Except for the NC group, which continued to receive PBS via gavage, the other groups drank water containing 3% sodium dextran sulfate (DSS) and continued to receive the corresponding test substance via gavage daily. The daily gavage dose for each group was 1 × 10⁻⁶ based on the viable bacterial count. 9 CFU / mL / mouse was administered via gavage after dilution to 200 μL with sterile PBS. The control group received an equal volume of sterile PBS via gavage. Mice had free access to food and water throughout the experiment. Body weight, fecal characteristics, and fecal blood were recorded daily for calculating the Disease Activity Index (DAI). Mice were euthanized at the end of the experiment, and their colons were harvested for measurement and subsequent pathological and molecular testing. The animal experimental design is shown in Table 1 below.
[0091] Table 1 Animal Experiment Design Table
[0092] 2. Changes in body weight and colon length in mice with colitis The effect of bilayer microcapsules on the body weight of mice with colitis was investigated by administering probiotic bilayer microcapsules via gavage and weighing the mice daily. Before daily gavage, the mice were weighed and their weight recorded; the weighing was repeated three times for each mouse, and the average value was taken.
[0093] The effect of bilayer microcapsules on the colon of mice with colitis was investigated by administering probiotic bilayer microcapsules daily via gavage and measuring the colon length. After gavage, the mice were euthanized by cervical dislocation, and the intestines were dissected, washed with sterile PBS buffer, dried, and their length measured and recorded.
[0094] 3. Disease Activity Index and Evaluation Methods The Disease Activity Index (DAI) is an important tool for assessing intestinal inflammation. During the experiment, daily changes in mouse body weight, fecal characteristics, and bleeding were recorded and scored using the DAI scoring scale. Specific scoring criteria are detailed in Table 2. The final DAI score was calculated as the average of the scores for body weight change, fecal characteristics, and bleeding.
[0095] Table 2. DAI scoring criteria for a mouse model of colitis
[0096] 4. Histopathological analysis of colon tissue, HE staining Mouse colons were collected and stored in cryovials at -80 °C. A small segment of the distal colon was excised and thoroughly rinsed with phosphate-buffered saline (PBS). This tissue was then immersed in a 4% paraformaldehyde fixation solution, repeatedly inverted to ensure complete fixation, and then stored at room temperature. After fixation, the colonic tissue underwent dehydration and paraffin embedding to prepare tissue sections. The sections were stained with hematoxylin and eosin (H&E) dye. Finally, microscopic observation was used to assess changes in mucosal damage and inflammatory cell infiltration in the colonic tissue.
[0097] 5. Determination of colonic tight junction protein mRNA expression The effects of bilayer microcapsules on the intestinal wall of mice with colitis were investigated by administering probiotic bilayer microcapsules daily via gavage and measuring the expression levels of tight junction proteins in the mouse intestine. The mRNA expression of intestinal barrier-related proteins (Zo-1 and Occludin-1) in the colon was analyzed using RT-qPCR.
[0098] like Figure 1 The results show that the high amylose corn starch on the left forms an opaque milky white suspension when dissolved in water, while the carboxymethylated CMS on the right forms a transparent or translucent homogeneous solution when dissolved in water. This indicates that carboxymethylation significantly improves the hydrophilicity and water solubility of starch, providing a good material for subsequent mannosylation modification and microcapsule preparation.
[0099] Figure 2 show, Figure 2 A is a raw material, and the high amylose corn starch granules have a regular polyhedral or spherical structure. Figure 2 B shows that the surface of the CMS particles exhibits obvious etching and roughening; Figure 2In C, the Man-CMS surface is more porous and irregular in morphology. This indicates that carboxymethylation and mannosylation modifications significantly alter the surface morphology of starch, increasing its specific surface area and reactivity, which is beneficial for subsequent encapsulation and cross-linking.
[0100] Fourier transform infrared spectra of high amylose corn starch, CMS, and Man-CMS are shown below. Figure 3 As shown. In the CMS spectrum, 1601 cm⁻¹ -1 and 1416 cm -1 New strong absorption peaks appear at these locations, which are attributed to the carboxyl group (-COO). - The asymmetric and symmetric stretching vibrations of Man-CMS confirmed the successful carboxymethylation modification of starch. Compared with CMS, Man-CMS showed a higher viscosity at 1597.7 cm⁻¹. -1 The increased intensity of the characteristic peak of the carboxylate in Man-CMS indicates that the carboxyl group in CMS underwent an amidation reaction with ethylenediamine, successfully introducing an amino group. Simultaneously, the peak intensity of Man-CMS at 2152 cm⁻¹... -1 The appearance of a new characteristic absorption peak indicates that D-mannose was successfully covalently modified onto the CMS backbone via a reductive amination reaction. The three peaks are located at 1050-1150 cm⁻¹. -1 The absorption peaks in the polysaccharide fingerprint region are basically consistent, indicating that the starch main chain structure remains intact.
[0101] Figure 4 This is a transmission electron microscope image of *Bifidobacterium longum* subsp. infantis KEY-1 naked bacteria. The bacteria are characterized by their typical short rod shape, clear edges, smooth surface, lack of obvious outer coating structure, and relatively uniform electron density.
[0102] Figure 5 This is a transmission electron microscope image of KEY-1-Fe / GSP monolayer-encapsulated probiotics. Compared to naked bacteria, a relatively dense coating structure is visible on the bacterial surface, with blurred edges and an increased overall electron density, indicating that the Fe / GSP metal-phenol network has been successfully coated on the bacterial surface.
[0103] Figure 6 This is a transmission electron microscope image of the KEY-1 / GM-CMS bilayer composite microcapsule of the present invention.
[0104] Compared to the monolayer-embedded samples, a structure with a contrasting appearance to the core region was further observed in the outer layer (indicated by the red arrow). This outer layer is continuously distributed on the outside of the microcapsules, indicating that Man-CMS has coated the inner surface. Combined with the results of layer-by-layer particle size increase and zeta potential changes, this supports the formation of a bilayer core-shell structure.
[0105] The final particle size and zeta potential of the prepared bilayer microcapsules are as follows: Figure 7 As shown. By Figure 7(A) shows that the average particle size of the KEY-1 group is 1677 nm, the average particle size of the KEY-1-Fe / GSP group is 2681 nm, and the average particle size of the bilayer microcapsule KEY-1 / GM-CMS group is 3324 nm. The layer-by-layer increase in microcapsule particle size indicates that the Man-CMS shell has been successfully coated on the surface of the inner network. Figure 7 (B) It is known that the average surface Zeta potential of the bilayer microcapsule KEY-1 / GM-CMS group is -11.30 mV, which is stronger than that of the KEY-1 group (-8.60 mV) and the KEY-1-Fe / GSP group (-10.01 mV). This confirms the successful construction of the outermost carboxyl-rich Man-CMS shell. This surface potential characteristic helps to improve the dispersion stability of the colloidal system.
[0106] KEY-1 group consists of KEY-1 bacterial suspension; The KEY-1-Fe / GSP group consists of a KEY-1-Fe / GSP monolayer encapsulated probiotic suspension. The KEY-1 / GM-CMS group consists of KEY-1 / GM-CMS bilayer composite microcapsules.
[0107] Depend on Figure 8 It was found that the encapsulation efficiency of monolayer KEY-1-Fe / GSP reached 96.1%, while the encapsulation efficiency of bilayer microcapsules formed by Man-CMS shell encapsulation was 83%. Although the encapsulation efficiency of the bilayer system was slightly lower than that of the monolayer, it still remained at a high level. This is mainly due to the additional operational steps introduced during the outer layer encapsulation process (such as drop addition, stirring, and centrifugal washing), resulting in a small loss of inner layer structure. However, the bilayer microcapsules showed a significant advantage in simulating gastrointestinal tolerance, demonstrating the synergistic effect of inner layer protection and outer layer pH responsiveness.
[0108] Figure 9 The viable bacterial survival of the KEY-1 group, KEY-1-Fe / GSP group, and KEY-1 / GM-CMS bilayer microcapsules of the present invention under simulated gastrointestinal digestive conditions is shown. After incubation in simulated gastric juice (SGF, pH 2.0) for 2 h, the viable bacterial count of the KEY-1 / GM-CMS bilayer microcapsules was 8.20 log₂O₅. 10 CFU / mL; after being transferred to simulated intestinal fluid (SIF, pH 6.8) and incubated for another 6 h, the viable count remained at 7.79 log. 10The viable count was CFU / mL, with a high survival rate. Compared with the naked bacteria KEY-1 and KEY-1-Fe / GSP groups, the decrease in viable bacteria count in the bilayer microcapsules was significantly smaller. These results indicate that the bilayer microcapsules, through the strong protection of the inner Fe / GSP layer and the pH-responsive properties of the outer Man-CMS layer, effectively resist the damage caused by gastric acid and the intestinal environment, significantly improving the gastrointestinal delivery capacity of probiotics.
[0109] Figure 10 This figure compares the encapsulation efficiency of different control groups with that of the bilayer microcapsules of this invention. As shown in the figure, the encapsulation efficiencies of the single-layer control groups were: KEY-1-Fe group 61.5%, KEY-1-GSP group 58.2%, KEY-1-Fe / EGCG group 75.8%, KEY-1-Fe / AP group 68.4%, KEY-1-Ca / GSP group 53.9%, and KEY-1 / GM-CMS bilayer composite microcapsule group 83%. In contrast, the encapsulation efficiency of the KEY-1-Fe / GSP (inner layer) of this invention reached 96.1%, significantly superior to other metal-polyphenol or single-layer control groups. This indicates that Fe... 3+ Multi-site coordination with grape seed polyphenols can form a denser network structure, thereby achieving efficient encapsulation of probiotics and providing a good inner layer foundation for the subsequent construction of bilayer microcapsules.
[0110] Figure 11 The changes in body weight of mice in each group during DSS induction are shown. Using the body weight on day 8 (the day DSS begins) as the baseline, the body weight of the normal control group (NC) mice steadily increased, reaching approximately 110% by day 14. The body weight of the model group (MC) mice steadily decreased after the start of DSS, reaching approximately 75% by day 14, the largest decrease. The KEY-1 group showed the most significant body weight decrease, with the monolayer KEY-1-Fe / GSP group decreasing to approximately 90%, while the bilayer KEY-1 / GM-CMS group showed the smallest decrease, maintaining approximately 92% by day 14. The results showed that the bilayer microcapsules could effectively alleviate the weight loss in DSS-induced colitis mice, and their protective effect was better than that of the KEY-1 group and the single-layer encapsulation group.
[0111] Figure 12 The changes in the disease activity index (DAI) of mice in each group during DSS induction were shown. The DAI of the normal control group (NC) mice remained at 0 throughout. In the model group (MC) mice, the DAI began to rise from day 11 and continued to increase, reaching approximately 4.0 on day 14, indicating the most severe disease activity. The DAI in the KEY-1 group was approximately 2.9 on day 14, the monolayer KEY-1-Fe / GSP group was approximately 2.2, while the DAI in the bilayer KEY-1 / GM-CMS group increased the slowest, reaching only approximately 1.3 on day 14. These results indicate that the bilayer microcapsules can inhibit the increase in the disease activity index of colitis induced by DSS.
[0112] Figure 13 The effects of gavage administration of PBS, KEY-1 probiotics, single-layer probiotic microcapsules, and double-layer probiotic microcapsules on colon length in DSS-induced colitis mice were investigated. Figure 13 As shown in Figure A, the colon in the NC group remained healthy and was the longest, while that in the MC group was the shortest, proving the successful establishment of the DSS model. Figure 13 As shown in B, the colon length of the KEY-1 / GM-CMS group was significantly higher than that of the KEY-1 group and the KEY-1-Fe / GSP group, and was close to that of the NC group. Moreover, the colon length of each experimental group was higher than that of the MC group, which proves that gavage administration of probiotics and microcapsules to DSS-induced colitis mice can restore the colon length of the mice, and the probiotic double-layer microcapsules have the best restoration effect.
[0113] Figure 14 The H&E staining pathological results of colon tissues from each group of mice are shown. In the normal control group (NC), the colonic mucosa structure was intact, with regular crypt arrangement, abundant goblet cells, and no obvious inflammatory cell infiltration. In the model group (MC), severe destruction and disappearance of crypt structure, a significant reduction in goblet cells, and extensive inflammatory cell infiltration were observed, indicating significant mucosal damage. In the KEY-1 group, crypt destruction was somewhat reduced, but inflammatory infiltration was still visible. In the monolayer KEY-1-Fe / GSP group, crypt structure was partially restored, and the degree of inflammation was further reduced. The bilayer KEY-1 / GM-CMS group had the colonic mucosa structure closest to the normal group, with more regular crypt arrangement, a significantly increased number of goblet cells, and the least inflammatory cell infiltration. These results indicate that bilayer microcapsules can effectively improve DSS-induced colonic tissue pathological damage, with a protective effect superior to the KEY-1 group and the monolayer embedding group.
[0114] Figure 15 The relative mRNA expression levels of tight junction proteins Occludin and ZO-1 in the colonic tissue of mice in each group were displayed. Compared with the normal control group (NC), the mRNA expression levels of Occludin and ZO-1 in the colon of model group (MC) mice were significantly reduced, indicating that DSS-induced intestinal barrier dysfunction. The expression levels of Occludin and ZO-1 in the KEY-1 group and the monolayer KEY-1-Fe / GSP group rebounded, but were still lower than those in the normal group. The mRNA expression levels of Occludin and ZO-1 in the bilayer KEY-1 / GM-CMS group were further increased, closest to the level of the normal control group. The results indicate that bilayer microcapsules can effectively upregulate the expression of tight junction proteins and improve DSS-induced intestinal barrier damage.
[0115] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. Microbial microcapsules based on grape seed polyphenol-metal network and modified starch, characterized in that, The microcapsules contain Bifidobacterium longum subsp. infantis encapsulated within an inner layer of grape seed polyphenol-iron ion metal-phenol network. Bifidobacterium longum subsp infantis A double-layered composite microcapsule with KEY-1 as the core and mannosylated carboxymethyl starch as the shell.
2. The microbial microcapsules based on grape seed polyphenol-metal network and modified starch according to claim 1, characterized in that, Bifidobacterium longum infant subspecies ( Bifidobacterium longum subsp infantis KEY-1 is deposited at Guangdong Provincial Center for Microbial Culture Collection, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Province, with accession number GDMCC No: 68845 and deposit date August 17, 2026.
3. The microbial microcapsules based on grape seed polyphenol-metal network and modified starch according to claim 1, characterized in that, Encapsulation efficiency: 82.5-83.4%; viable bacterial count after 2 hours of simulated gastric digestion: 8.15-8.23 log. 10 CFU / mL, viable bacterial count after 4 h of simulated intestinal digestion was 7.72-7.81 log. 10 CFU / mL.
4. The method for preparing microbial microcapsules based on grape seed polyphenol-metal network and modified starch according to any one of claims 1-3, characterized in that, Includes the following steps: S1, Preparation of carboxymethyl starch: High amylose corn starch is alkalized and carboxymethylated, then washed and dried to obtain carboxymethyl starch powder; S2, Preparation of mannosaccharified carboxymethyl starch: Carboxymethyl starch is introduced with amino groups through an amidation reaction, and then grafted with D-mannose through a reducing amination reaction to obtain mannosaccharified carboxymethyl starch; S3, Preparation of Bifidobacterium longum infant subsp. KEY-1 embedded in the inner metal-phenol network: After activating Bifidobacterium longum infant subsp. KEY-1, it was mixed with FeCl3 and grape seed polyphenol GSP. Through metal-phenol coordination self-assembly, a monolayer probiotic solution of KEY-1 embedded in the Fe / GSP metal-phenol network was obtained, abbreviated as KEY-1-Fe / GSP. S4, Preparation of bilayer composite microcapsules: The mannosaccharified carboxymethyl starch obtained in step S2 is made into a mannosaccharified carboxymethyl starch suspension receiving liquid. The KEY-1-Fe / GSP from step S3 is added dropwise to the mannosaccharified carboxymethyl starch suspension receiving liquid. After stirring, crosslinking, centrifugation, washing, and freeze drying, microcapsules based on grape seed polyphenol-metal network and modified starch are obtained.
5. The preparation method according to claim 4, characterized in that, In S1, the preparation of carboxymethyl starch is as follows: 10-15 g of high amylose corn starch is weighed and added to a three-necked flask containing 90-120 mL of isopropanol solvent; the stirring speed is 500-600 rpm, and then 12-18 mL of 14.67 mol / L NaOH solution is slowly added dropwise at a rate of 0.5-1.0 mL / min for alkalization; after alkalization for 20 min, 2.5-3.5 g of chloroacetic acid is added to the system, and the system is heated to 35-45℃ for 2-3 h; after the reaction is complete, the product is filtered, the precipitate is suspended in 95% ethanol, and the pH is adjusted to 5.5-6.5 with 50% acetic acid, filtered again, and the precipitate is washed with 85% ethanol until 0.1 g is used. Chloride ions were not detected in mol / L silver nitrate. The sample was washed with anhydrous ethanol 2-3 times to remove water, and the precipitate was dried in an oven at 40-45℃ for 20-30 hours. Finally, the sample was ground into fine powder and passed through a 60-mesh sieve to obtain carboxymethyl starch powder. The amylose content of high-amylose corn starch is 55%-70% by mass.
6. The preparation method according to claim 5, characterized in that, S2 includes the following steps: S21: Weigh 6-8g of the carboxymethyl starch powder prepared in step S1 and completely dissolve it in 500 mL of MES buffer. Add 3.0-3.8g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1.8-2.3g of N-hydroxysuccinimide (NHS) to the solution sequentially for carboxyl activation for 1.5h. Then, add 18-24ml of ethylenediamine dropwise to the system. After the addition is complete, continue the reaction for 24h. After the reaction is complete, transfer the reaction solution to 1mM HCl solution for dialyzing for 24h, then transfer it to deionized water for dialyzing for 48-72h. Finally, collect the substance in the dialysis bag and freeze-dry it to obtain aminoethylated carboxymethyl starch. S22, Preparation of mannosyl carboxymethyl starch by reducing amination reaction: Weigh all the aminoethylated carboxymethyl starch obtained in step S21 and completely dissolve it in 300 mL PBS buffer. Add 12-15 g of D-mannose and 3.5-4 g of reducing agent sodium cyanoborohydride to the solution in sequence. Place the reaction system in a sealed environment at 37 ℃ for 48-72 h. After the reaction is completed, transfer the entire reaction system to a dialysis bag and dialyze with ultrapure water for 72 h to remove unreacted small molecule impurities. After dialysis, collect the substance in the dialysis bag and freeze-dry it to obtain the final mannosyl carboxymethyl starch.
7. The preparation method according to claim 6, characterized in that, S3 includes the following steps: S31, activate Bifidobacterium longum subsp. infantis KEY-1 to obtain activated bacterial solution of Bifidobacterium longum subsp. infantis KEY-1; S32, take 1 mL of bacteria with a concentration of 1×10⁻⁶. 9 CFU / mL of activated Bifidobacterium longum subsp. infantis KEY-1 bacterial suspension was collected by centrifugation, the supernatant was discarded, and the suspension was resuspended in 1 mL PBS buffer to obtain KEY-1 bacterial suspension. The bacterial concentration of KEY-1 bacterial suspension was 1×10⁻⁶. 9 CFU / mL; separately prepare a 5 mg / mL FeCl3 solution and a 20 mg / mL grape seed polyphenol GSP solution; take 100 μL of the above KEY-1 bacterial suspension, mix with 880 μL PBS buffer, and then slowly add 10 μL of FeCl3 solution and 10 μL of grape seed polyphenol GSP solution at a rate of 0.5-1.0 mL / min respectively; after the sample addition is completed, mix at room temperature for 20 min to finally obtain 1 mL of KEY-1 monolayer probiotic solution embedded in the Fe / GSP metal-phenol network, abbreviated as KEY-1-Fe / GSP.
8. The preparation method according to claim 7, characterized in that, S4 includes the following steps: S41, firstly, the mannosaccharified carboxymethyl starch obtained in step S2 is completely dissolved in ultrapure water to prepare a 1% (w / w) mannosaccharified carboxymethyl starch suspension receiving solution; the 1% mannosaccharified carboxymethyl starch suspension receiving solution is placed on a magnetic stirrer, and the stirring speed is controlled at 300-500 rpm; then, the KEY-1-Fe / GSP prepared in step S3 is loaded into a syringe and dripped uniformly into the above 1% mannosaccharified carboxymethyl starch suspension receiving solution at a constant flow rate of 200 μL / min through the coaxial microneedle of the syringe; the volume ratio of the KEY-1-Fe / GSP to the mannosaccharified carboxymethyl starch suspension receiving solution is controlled at 1:(8-12). S42, after the addition is complete, continue the reaction for 30 min at room temperature and with stirring at 600 rpm; after the reaction is complete, transfer the resulting mixture to a centrifuge tube and centrifuge at 3000-5000 rpm for 5 min to collect the microcapsule precipitate. Discard the supernatant and wash the precipitate 2-3 times with deionized water. Finally, freeze-dry the washed precipitate under vacuum to obtain the final KEY-1 / GM-CMS bilayer composite microcapsule solid powder, which is a microcapsule based on grape seed polyphenol-metal network and modified starch.
9. The preparation method according to claim 8, characterized in that, In S42, the vacuum freeze-drying process parameters are as follows: pre-freeze at -80℃ for 10-15 hours; maintain the cold trap temperature at -60℃ and the vacuum pressure at 5-20Pa; during the main drying stage, gradually increase the sample temperature from -40℃ to -20℃ for 20-30 hours; during the secondary drying stage, increase the sample temperature from -20℃ to 20-25℃ for 6-12 hours until the sample moisture content is below 5%; after freeze-drying, slowly open the gas inlet and wait 4-5 minutes before removing the sample.
10. The application of microbial microcapsules based on grape seed polyphenol-metal network and modified starch to improve gut health according to any one of claims 1-3, characterized in that, Application of microcapsules in the preparation of drugs to improve gut health.
